Compare Becton Dickinson and Co (BDX) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Invesco S&P 500 Momentum ETF — how do they compare? Becton Dickinson and Co trades at $180.75 (market cap $49.41B), while Invesco S&P 500 Momentum ETF trades at $150. The key difference: Becton Dickinson and Co pays a 2.32% dividend while Invesco S&P 500 Momentum ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, Invesco S&P 500 Momentum ETF nearer its low. Which is the better fit depends on your goals.
| BDX | SPMO | |
|---|---|---|
Market Cap | $49.41B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $185.39 | $161.66 |
52-Week Low | $138.62 | $107.84 |
Enterprise Value | $65.51B | — |
Dividend Yield | 2.32% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
